Norah Lynn Henry, MD, PhD
Manage Your Profile
About
N. Lynn Henry, MD, PhD is a Professor of Internal Medicine and Associate Director for Community Outreach and Engagement for the Rogel Cancer Center. She is also Co-Chair of the Symptom Management and Quality of Life Committee for the SWOG National Cancer Treatment Network research base. She was formerly Interim Division Chief and section head for breast oncology in the Division of Hematology/Oncology, associate director of Training, Research, and Education for the Rogel Cancer Center, and Co-Director of the Michigan Breast Oncology Quality Consortium. She completed her undergraduate training at Louisiana State University, her doctoral degree in structural biology at Stanford University School of Medicine, and her medical degree at Washington University School of Medicine in St Louis, MO. She then completed her internal medicine residency training at Brigham and Women's Hospital in Boston, MA, followed by hematology/oncology fellowship at the University of Michigan. Dr. Henry cares for patients with all types and stages of breast cancer. Her research is focused on toxicity of therapy for patients with breast cancer, including understanding the mechanisms of development of side effects, identifying which patients are likely to tolerate treatment, and examining interventions to manage toxicity. She has received grant funding from the National Cancer Institute, the American Cancer Society, the Damon Runyon Cancer Research Foundation, the V Foundation, the Hope Foundation for Cancer Research, and the Breast Cancer Research Foundation.
Qualifications
-
Hematology/Oncology FellowshipUniversity of Michigan, United States
2004 - 2007
Clinical Fellowship
-
Internal Medicine ResidencyBrigham and Women's Hospital, Boston, MA, United States
2001 - 2004
Residency
-
MDWashington University School of Medicine, 660 S. Euclid, St Louis, Missouri, 63110, United States
1996 - 2001
-
PhDStanford University School of Medicine, 300 Pasteur Drive, Stanford, California, 94305, United States
1991 - 1996
Center Memberships
-
Center MemberTaubman Institute
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberRogel Cancer Center
-
Center Membere-Health and Artificial Intelligence Initiative
-
Center MemberAI and Digital Health Innovation
-
Center MemberCenter for Global Health Equity
Recent Publications
-
Henry N, Griffith K, Kidwell K, Kozar S, Scheu K, Cobain E, Armstrong J, Secor M, Snyder S, Zick S. npj Breast Cancer, 2026 Oct 16;Journal ArticleRandomized clinical trial of self-acupressure for aromatase-inhibitor associated musculoskeletal symptoms
DOI:10.1038/s41523-026-01066-0 -
Henry L. 2026 Sep 21;PresentationThe Ripple Effect: How De-escalation of Surgery and Radiation Approaches Shape Systemic Therapy Decisions
-
Henry L. 2026 Aug 22;PresentationStrategies to mitigate musculoskeletal symptoms using nonpharmacologic approaches
-
Henry L. 2026 Aug 22;PresentationTargeting the gut microbiome to manage arthralgia in patients treated with aromatase inhibitors
-
Jones SMW, Till C, Unger JM, Hershman DL, Henry NL, Berry DL, Patel S, Hall E. Journal of Patient-Reported Outcomes, 2026 Aug 19;Journal ArticleComparison of five definitions of meaningful change on patient-reported outcomes in four SWOG clinical trials
DOI:10.1186/s41687-026-01182-2 -
Rocha Lima CMSP, Yothers G, George TJ, Hochster HS, Sanoff HK, Cohen DJ, Guthrie KA, Jacobs SA, Saeed A, Kopetz S, Colangelo LH, Freeman TJ, Cole SW, Khalil M, Devanna S, Zuckerman DS, Hong TS, Henry NL, Ganz PA, Blanke CD, Wolmark N, Overman MJ. Journal of Clinical Oncology, 2026 Sep 21;Journal ArticleCOMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
DOI:10.1200/JCO-25-03052 -
Jagsi R, Meisner A, Chalasani P, Lew D, Barlow WE, Bellon JR, Henry NL, Matuszak MM, Moran JM, Pierce LJ, Rakovitch E, Reyes SJ, Speers C, Unger JM, White JR, Woodward WA, Zellars RC, Pusztai L, Sharma P. Int J Radiat Oncol Biol Phys, 2026 Jul 28;Journal ArticleAdverse Events in a Randomized Trial Comparing Radiotherapy with or without Olaparib for Inflammatory Breast Cancer.
DOI:10.1016/j.ijrobp.2026.07.029 PMID: 42520859 -
Henry L. 2026 Aug 8;PresentationSurvivorship: ASCO Updates
Featured News & Stories